NMN Dosage: Human Doses From 100 mg to 2,000 mg Explained

There is no clinically established “anti-aging dose” of NMN. Human studies have tested doses from roughly 250 mg/day at the lower end to 2,000 mg/day in specialized pharmacokinetic programs, with many modern trials clustering around 250–1,200 mg/day.

The useful question is not “what dose is most popular?” but what did each dose actually do in a controlled human study, for how long, in whom, and with what formulation?

NMN dosage used in human studies

Daily NMN dose	Example human research	What it tells us
250 mg	Older-adult, sleep/physical-function and insulin-sensitivity trials	Common lower clinical-research dose with biological activity
300 mg	Multicenter Uthever trial; dose-ranging RCT	Raises NAD-related measures; selected functional outcomes studied
600 mg	Dose-ranging RCT	Higher mid-range research dose
900 mg	Dose-ranging RCT	Upper arm of a major multicenter dose study
1,000 mg	Head-to-head NMN-vs-NR study; MIB-626 pharmacokinetics	Robust NAD+ elevation over 14 days
1,200 mg	Short BFR-exercise crossover study	Very short-term high intake with muscle inflammatory/remodeling effects
2,000 mg	MIB-626 pharmacokinetic study	High-dose pharmaceutical-grade research exposure; not a general consumer recommendation

100–500 mg: the original single-dose human safety study

The first published human NMN study gave 10 healthy men a single oral dose of 100, 250 or 500 mg on separate study visits. The doses were generally well tolerated and did not produce clinically significant changes in vital signs, ophthalmic examinations, sleep-quality scores or routine laboratory testing. ^[1]

This study is why 100 mg belongs in a complete map of human NMN exposure. It should not be interpreted as evidence that 100 mg/day is an effective long-term dose: it was an acute safety/pharmacokinetic study, not a repeated-dose efficacy trial.

There is no NMN RDA or established universal upper limit

NMN does not have an established Recommended Dietary Allowance, Daily Value or universally accepted Tolerable Upper Intake Level. The 300 mg/day figure in EFSA's 2026 opinion applies to the specified β-NMN material and proposed conditions evaluated in that novel-food safety assessment; it is not a general NMN RDA or an upper limit proving that 301 mg/day is unsafe. ^[2]

Likewise, the fact that 1,250–2,000 mg/day has been studied for short periods does not establish those amounts as appropriate for indefinite consumer use.

250 mg/day

The Yoshino RCT in postmenopausal women with prediabetes used 250 mg/day and reported improved muscle insulin sensitivity. ^[3]

Kim and colleagues used 250 mg/day for 12 weeks in older Japanese adults. ^[4] Morifuji and colleagues also used 250 mg/day for 12 weeks, reporting increased NAD+ and some secondary walking and sleep signals. ^[5]

These studies show that 250 mg/day is biologically active. They do not establish it as an optimal longevity dose.

300, 600 and 900 mg/day

The multicenter randomized dose-ranging study compared placebo with 300, 600 and 900 mg/day NMN. ^[6]

It observed dose-related changes in circulating NAD and selected performance outcomes. Dose-response within a short trial does not prove that 900 mg/day is better for long-term health than 300 mg/day.

1,000 mg/day

In the 2026 direct comparison, 1,000 mg/day NMN for 14 days roughly doubled baseline whole-blood NAD+, producing a response similar to 1,000 mg/day NR. ^[7]

A separate MIB-626 study tested 1,000 and 2,000 mg/day of a pharmaceutical-grade microcrystalline NMN formulation. Both increased NAD-related measures. ^[8]

1,200 mg/day

A 2026 crossover trial gave young men 1,200 mg/day NMN for seven days before blood-flow-restriction resistance exercise. NMN dampened several acute inflammatory and muscle-remodeling responses. ^[9]

The study did not measure long-term gains, so it does not prove harm. It shows that high-dose biological effects can be context-dependent.

2,000 mg/day

Two grams per day has been used in short MIB-626 pharmacokinetic work. ^[10] The product was a specific pharmaceutical-grade microcrystalline polymorph, the sample was small, and duration was 14 days.

It is inappropriate to translate “2,000 mg was studied for two weeks” into “2,000 mg is safe or superior for years.”

What dose did the 2026 meta-analysis cover?

The 2026 systematic review/meta-analysis included randomized trials using approximately 250–2,000 mg/day over 14 days to 24 weeks. ^[11] NMN appeared reasonably well tolerated short term, but most pooled metabolic outcomes did not improve significantly.

How to interpret NMN dose labels

What do NMN 9000, 12000, 18000, 30000 or 60000 mean?

These large numbers usually describe the total labeled NMN in the entire bottle, not the amount you should take each day.

For example, a product marketed as “NMN 18000” may contain 300 mg per capsule × 60 capsules = 18,000 mg total. A “NMN 12000” bottle may similarly total 12,000 mg across all tablets or capsules. The number is therefore a packaging/quantity convention, not a clinical dose, purity percentage or evidence grade.

When comparing one of these products with human trials, ignore the large front-label number and find:

• β-NMN milligrams per capsule or serving;
• the recommended number of servings per day;
• the actual daily β-NMN exposure;
• the number of days the bottle supplies; and
• whether the finished product has current identity/potency testing.

An “18,000 mg” bottle could still deliver only 300–600 mg/day. Conversely, a huge bottle-total number does not prove that the material is purer or more effective.

Does body weight determine NMN dose?

Most consumer-style human NMN trials use fixed doses rather than mg/kg dosing. There is no validated clinical formula such as “X mg per kilogram for longevity.” Animal dose conversions are not personal dosing calculators.

Timing and administration

Morning or night?

Timing evidence is much thinner than dose evidence. The Kim trial compared morning with afternoon administration and found some favorable afternoon signals, but that does not establish a universal chronotherapy rule. ^[12]

See how and when to take NMN.

With food or on an empty stomach?

Human trials have not established a clinically superior empty-stomach protocol. New human data suggest gut-microbial processing contributes to how NMN enters systemic NAD metabolism. ^[13]

Standard oral vs sublingual dose

The 2026 crossover study found differences in early circulating terminal metabolites after sublingual versus oral NMN. ^[14] It did not establish a dose-conversion ratio or superior clinical outcomes.

Safety and dose limits

What does EFSA's 300 mg/day assessment mean?

EFSA evaluated a specific chemically synthesized β-NMN material proposed at up to 300 mg/day for adults excluding pregnant and lactating women and concluded that the evaluated product was safe under those conditions. ^[15]

This is a regulatory safety assessment, not a declaration that 300 mg/day is the ideal efficacy dose.

High-dose safety data

Randomized studies have examined higher-dose or overdose-style intake without uncovering a clear short-term safety signal in the studied adults. ^{[16] [17]}

How to choose an NMN dose

Why product quality changes the meaning of a “500 mg” dose

Independent testing found large deviations between label claim and measured NMN in commercial products. ^[18] Isomer-specific testing also found undeclared or inaccurately labeled composition. ^[19]

Before debating 500 versus 1,000 mg, confirm batch-specific identity and assay testing. See NMN purity and COAs.

A practical way to read NMN dosage claims

• Ask whether the number comes from a human trial or marketing.
• Check the exact formulation used.
• Check the population and duration.
• Check whether the outcome was NAD+, a surrogate, a secondary endpoint or a clinical outcome.
• Do not assume higher NAD+ automatically means greater health benefit.
• Do not use a short high-dose safety study as proof of indefinite high-dose safety.

Studied dose ≠ optimal dose: why the “optimal dose” is still unanswered

An optimal clinical dose would maximize a meaningful benefit while minimizing cost and risk. NMN research has not yet identified that point because studies use different populations, formulations, durations and endpoints. A dose that maximizes blood NAD+ may not maximize physical function, insulin sensitivity or long-term safety.

Can blood NAD testing personalize NMN dose?

Post-hoc research suggests baseline NAD status and person-to-person response can vary. ^[20] Berven also observed marked interindividual variation in precursor response. ^[21]

That makes personalization scientifically interesting, but no validated clinical algorithm tells consumers to titrate NMN to one target blood NAD number.

Why the label dose may not be the real dose

Independent product testing has documented large label-claim deviations. ^[22] A 500 mg serving is only meaningful if the finished product actually contains roughly that amount of the claimed β-NMN. See our purity and COA guide.

A better way to choose a dose

• Start with the human trial closest to the outcome and population you care about.
• Match the exact formulation as closely as practical rather than only the milligram number.
• Do not escalate solely to chase a larger blood NAD value.
• Consider whether the evidence was collected over days, weeks or months.
• Review medications and medical conditions before high-dose experimentation.
• Verify the finished-product potency.

Related NMN guides

• how and when to take NMN
• NMN dose and safety
• human NMN trial protocols
• how to verify the dose on an NMN product
• NMN products compared

Bottom line

Human research shows biological activity across several hundred milligrams per day and higher, but it has not identified one longevity dose that maximizes benefit and minimizes risk. Choose evidence by endpoint and formulation—not by the largest number on a bottle.